793 related articles for article (PubMed ID: 8893413)
1. The long QT syndrome: new diagnostic and therapeutic approach in the era of molecular biology.
Priori SG; Cantù F; Schwartz PJ
Schweiz Med Wochenschr; 1996 Oct; 126(41):1727-31. PubMed ID: 8893413
[TBL] [Abstract][Full Text] [Related]
2. Molecular biology of the long QT syndrome: impact on management.
Priori SG; Napolitano C; Paganini V; Cantù F; Schwartz PJ
Pacing Clin Electrophysiol; 1997 Aug; 20(8 Pt 2):2052-7. PubMed ID: 9272507
[TBL] [Abstract][Full Text] [Related]
3. Differential response to Na+ channel blockade, beta-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long-QT syndrome.
Priori SG; Napolitano C; Cantù F; Brown AM; Schwartz PJ
Circ Res; 1996 Jun; 78(6):1009-15. PubMed ID: 8635231
[TBL] [Abstract][Full Text] [Related]
4. A molecular basis for the therapy of the long QT syndrome.
Priori SG; Napolitano C; Schwartz PJ
Arch Mal Coeur Vaiss; 1996 Sep; 89(9):1185-7. PubMed ID: 8952843
[TBL] [Abstract][Full Text] [Related]
5. Sinus node function and ventricular repolarization during exercise stress test in long QT syndrome patients with KvLQT1 and HERG potassium channel defects.
Swan H; Viitasalo M; Piippo K; Laitinen P; Kontula K; Toivonen L
J Am Coll Cardiol; 1999 Sep; 34(3):823-9. PubMed ID: 10483966
[TBL] [Abstract][Full Text] [Related]
6. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy.
Schwartz PJ; Priori SG; Locati EH; Napolitano C; Cantù F; Towbin JA; Keating MT; Hammoude H; Brown AM; Chen LS; Colatsky TJ
Circulation; 1995 Dec; 92(12):3381-6. PubMed ID: 8521555
[TBL] [Abstract][Full Text] [Related]
7. High affinity open channel block by dofetilide of HERG expressed in a human cell line.
Snyders DJ; Chaudhary A
Mol Pharmacol; 1996 Jun; 49(6):949-55. PubMed ID: 8649354
[TBL] [Abstract][Full Text] [Related]
8. The inherited long QT syndrome: from ion channel to bedside.
Vincent GM; Timothy K; Fox J; Zhang L
Cardiol Rev; 1999; 7(1):44-55. PubMed ID: 10348966
[TBL] [Abstract][Full Text] [Related]
9. Modulating effects of age and gender on the clinical course of long QT syndrome by genotype.
Zareba W; Moss AJ; Locati EH; Lehmann MH; Peterson DR; Hall WJ; Schwartz PJ; Vincent GM; Priori SG; Benhorin J; Towbin JA; Robinson JL; Andrews ML; Napolitano C; Timothy K; Zhang L; Medina A;
J Am Coll Cardiol; 2003 Jul; 42(1):103-9. PubMed ID: 12849668
[TBL] [Abstract][Full Text] [Related]
10. Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.
Witchel HJ; Hancox JC
Clin Exp Pharmacol Physiol; 2000 Oct; 27(10):753-66. PubMed ID: 11022966
[TBL] [Abstract][Full Text] [Related]
11. The long QT syndromes: genetic basis and clinical implications.
Chiang CE; Roden DM
J Am Coll Cardiol; 2000 Jul; 36(1):1-12. PubMed ID: 10898405
[TBL] [Abstract][Full Text] [Related]
12. The molecular genetics of the long QT syndrome: genes causing fainting and sudden death.
Vincent GM
Annu Rev Med; 1998; 49():263-74. PubMed ID: 9509262
[TBL] [Abstract][Full Text] [Related]
13. Molecular biology and cellular mechanisms of Brugada and long QT syndromes in infants and young children.
Antzelevitch C
J Electrocardiol; 2001; 34 Suppl():177-81. PubMed ID: 11781953
[TBL] [Abstract][Full Text] [Related]
14. Multi-undulant T-U-wave, sinus bradycardia and long QT syndrome: a possible phenotype of mutant genes controlling the inward potassium rectifiers.
Shen CT; Wu YC; Yu SS; Wang NK
Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi; 1997; 38(4):267-75. PubMed ID: 9297927
[TBL] [Abstract][Full Text] [Related]
15. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes.
Yang P; Kanki H; Drolet B; Yang T; Wei J; Viswanathan PC; Hohnloser SH; Shimizu W; Schwartz PJ; Stanton M; Murray KT; Norris K; George AL; Roden DM
Circulation; 2002 Apr; 105(16):1943-8. PubMed ID: 11997281
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
17. Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome.
Sicouri S; Antzelevitch D; Heilmann C; Antzelevitch C
J Cardiovasc Electrophysiol; 1997 Nov; 8(11):1280-90. PubMed ID: 9395171
[TBL] [Abstract][Full Text] [Related]
18. QT interval prolongation and cardiac risk assessment for novel drugs.
Picard S; Lacroix P
Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
[TBL] [Abstract][Full Text] [Related]
19. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
[TBL] [Abstract][Full Text] [Related]
20. Molecular determinants of dofetilide block of HERG K+ channels.
Ficker E; Jarolimek W; Kiehn J; Baumann A; Brown AM
Circ Res; 1998 Feb; 82(3):386-95. PubMed ID: 9486667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
